Shopping Cart
- Remove All
Your shopping cart is currently empty
PKI 14-22 amide, myristoylated Acetate
Catalog No. T21983L
Alias PKI 14-22 amide, myristoylated Acetate(201422-03-9 Free base)
PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP.
PKI 14-22 amide, myristoylated Acetate
Catalog No. T21983LAlias PKI 14-22 amide, myristoylated Acetate(201422-03-9 Free base)
PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $298 | In Stock | |
| 5 mg | $671 | In Stock | |
| 10 mg | $997 | In Stock | |
| 25 mg | $1,480 | In Stock | |
| 50 mg | $1,990 | In Stock | |
| 100 mg | $2,690 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $1,290 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PKI 14-22 amide, myristoylated Acetate"
Acefylline
Theophyllineacetic acid, Theophylline-7-acetic acid, Carboxymethyltheophylline, acetyloxytheophylline
T2205652-37-9
Acefylline (Theophylline-7-acetic acid), a stimulant drug of the xanthine chemical class, acts as an adenosine receptor antagonist. It is combined with diphenhydramine in the pharmaceutical preparation Etanautine to help offset its stimulant effects
- $33
Size
QTY
Staurosporine
Cited
CGP 41251, Antibiotic AM-2282, AM-2282
T668062996-74-1
Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
Size
QTY
CitedJAK1/2/3 Inhibitor 1
T7750416234-14-3
JAK1/2/3 Inhibitor 1 is a potent protein kinase inhibitor.JAK1/2/3 Inhibitor 1 has antitumor activity that inhibits the growth of a variety of cancer cell lines. It inhibits the growth of cancer cells by binding to the cancer cell backbone and inhibiting the production of new proteins.
- $50
Size
QTY
Capivasertib Cited
AZD5363
T19201143532-39-1
Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.
- $34
Size
QTY
Cited8-Bromo-cAMP sodium salt Cited
8-Bromo-cAMP(sodium salt), 8-Bromo-cAMP, 8-Br-Camp sodium salt
T674776939-46-3
8-Bromo-cAMP sodium salt (8-Br-Camp sodium salt) is a long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase（PKA）, but resistant to degradation by cyclic AMP phosphodiesterase.
- $41
Size
QTY
CitedRo-3306 Cited
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
- $32
Size
QTY
CitedFasudil hydrochloride Cited
HA-1077 hydrochloride, HA-1077, Fasudil HCl, Fasudil (HA-1077) HCl, AT-877
T3060105628-07-7
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
- $35
Size
QTY
CitedEllagic acid Cited
Gallogen, Elagostasine
T0465476-66-4
Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.
Carbonic AnhydraseCasein KinaseEndogenous MetaboliteHedgehog/SmoothenedPKAPKCReactive Oxygen SpeciesSykTopoisomerase
- $44
Size
QTY
CitedGSK180736A
GSK180736
T3513817194-38-0
GSK180736A is an effective and selective GRK2 inhibitor (IC50: 0.77 μM) and >100-fold selectivity over other GRKs. It is a weak inhibitor of PKA (IC50: 30 μM), but highly effective against ROCK1 (IC50: 100 nM).
- $35
Size
QTY
Daphnetin
Daphnetol, 7,8-Dihydroxycoumarin
T2851486-35-1
Daphnetin (7,8-Dihydroxycoumarin), a natural coumarin derivative, is a protein kinase inhibitor with inhibitory for EGFR (IC50: 7.67 μM), PKA (IC50: 9.33 μM), and PKC (IC50: 25.01 μM), also exhibit anti-oxidant and anti-inflammatory activities.
- $43
Size
QTY
Select Batch
Purity:96.34%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP. |
| In vitro | ?Myristoylated PKI 14-22 amide reduced the IgG-mediated phagocytic response in a manner of dose-dependent.?When the concentration is higher than 10 μM, PKI 14-22 amide can inhibit neutrophil adhesion, which make the phagocytosis measurements impossible to perform |
| Alias | PKI 14-22 amide, myristoylated Acetate(201422-03-9 Free base) |
| Molecular Weight | 1269.54 |
| Formula | C55H104N20O14 |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/ml (43.32 mM)  | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy PKI 14-22 amide, myristoylated Acetate | purchase PKI 14-22 amide, myristoylated Acetate | PKI 14-22 amide, myristoylated Acetate cost | order PKI 14-22 amide, myristoylated Acetate | PKI 14-22 amide, myristoylated Acetate chemical structure | PKI 14-22 amide, myristoylated Acetate in vitro | PKI 14-22 amide, myristoylated Acetate formula | PKI 14-22 amide, myristoylated Acetate molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.